
|Articles|May 1, 2002
Second course of efalizumab improves response in psoriatics
New Orleans-Psoriatic patients who responded partially or not at all to initial treatment with efalizumab (Xanelim) responded more positively and without significant adverse events during a second course of treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











